New Psoriasis Therapy Shows Promise in Extended Clinical Trial

Soligenix Inc. has released findings from an extended Phase 2a trial of SGX302, a new photodynamic therapy for psoriasis. The treatment uses light-activated synthetic hypericin and has shown promise in patients with mild-to-moderate symptoms. An improved gel formulation was tested over an 18-week period, offering easier application and better tolerance among participants.

SGX302 works by applying a gel containing synthetic hypericin to psoriasis lesions, which is then activated by visible light. In the trial extension, patients received the therapy twice weekly for 18 weeks. The updated gel version was designed for smoother dispensation and more comfortable skin application compared to earlier formulations.

All participants in cohort 3 tolerated the treatment well, with no drug-related side effects reported. The extended study provided additional safety data and helped refine the gel’s formulation for future testing. Unlike some existing psoriasis treatments, SGX302 does not carry the same risk of carcinogenic effects, potentially offering a safer alternative for long-term use.

The Phase 2a extension confirms the improved gel’s safety and ease of use. Soligenix plans to use these findings to guide further clinical development of SGX302. If successful, the therapy could become a first-in-class option for psoriasis patients seeking non-carcinogenic treatment.